A retrospective study comparing multiple ctDNA methylation markers with PSA levels and PSMA PET/CT results in patients with various localized and advanced cancer subtypes undergoing different therapies has indicated the promise of ctDNA methylation markers for minimally invasive detection and prognosis of CRPC. Here, KLK3 is linked to cancer.